Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of two drug combinations Cabotegravir Ultra Long-Acting CAB ULA plus Rilpivirine Ultra Long-Acting RPV ULA, and Cabotegravir Long-Acting CAB LA plus Rilpivirine Long-Acting RPV LA in adults and adolescents living with HIV who have their virus suppressed through antiretroviral therapy ART. This phase III trial aims to compare these treatments to understand their impact on maintaining viral suppression. Participants receive either the CAB ULA plus RPV ULA combination or the CAB LA plus RPV LA combination. These medications are administered as long-acting injectable drugs. The study uses a randomized, parallel-group design where participants are assigned to one of these two treatment groups to compare outcomes over time. During the trial, participants will be monitored closely with regular assessments including measuring plasma HIV-RNA levels, tracking any virologic failure, and evaluating drug-related adverse events. Laboratory tests will monitor drug concentrations and immune cell counts CD4 cells. The main outcome is the percentage of participants with HIV-RNA levels above 50 copiesmL at month 11. The study follows participants for up to 23 months to assess longer-term effects and safety.
Actively Recruiting
Researchers are evaluating the efficacy of perioperative dostarlimab compared with the standard of care in participants with untreated T4N0 or Stage III resectable colon cancer that shows defective mismatch repair or high microsatellite instability dMMRMSI-H. This phase 3, open-label, randomized study focuses on these specific colon cancer patients to assess if dostarlimab can improve outcomes compared to current treatments. Participants are randomly assigned to receive either dostarlimab before and after surgery or the standard of care treatments, which include FOLFOX or CAPEOX chemotherapy or post-surgery observation. Dostarlimab is given as monotherapy during the perioperative period. The study carefully monitors participants for up to approximately 5 years to evaluate long-term effects. During the trial, participants undergo regular assessments including event-free survival reviewed by blinded independent central review, overall survival, and pathological response evaluations. Safety is closely monitored by tracking adverse events, immune-related effects, and serum concentrations of dostarlimab across treatment cycles. The study involves frequent follow-ups to understand treatment impact and ensure participant well-being throughout the extended observation period.